Johnson & Johnson's
) third quarter 2012 results exceeded expectations with earnings
(excluding special items) coming in at $1.25 per share, 5 cents
above the Zacks Consensus Estimate and 0.8% above the year-ago
earnings of $1.24 per share.
Despite the negative impact of currency fluctuation, Johnson
& Johnson recorded growth on the back of strong product
Revenues increased 6.5% year-over-year to $17.1 billion, beating
the Zacks Consensus Estimate of $16.9 billion. While operational
factors favorably impacted sales by 10.8%, currency fluctuations
had a negative impact of 4.3%. Results included the impact of the
recently completed Synthes acquisition, which contributed 5.8% to
global operational sales growth.
Including one-time items, Johnson & Johnson reported third
quarter earnings of $1.05 per share, 8.7% below the year-ago
earnings of $1.15.
The Quarter in Detail
Third quarter sales increased 13.4% in the domestic market.
Meanwhile, international sales grew 1.4%, consisting of 8.9%
operational growth and 7.5% negative currency impact. While both
the Pharmaceutical and the Medical Devices & Diagnostics
segments posted an increase in sales, the Consumer segment recorded
a decline in sales.
The Medical Devices & Diagnostics segment posted sales of
$7.1 billion, up 12.5% year-over year. While operational factors
positively impacted Medical Devices & Diagnostics segment sales
by 16.1%, foreign exchange movement negatively impacted sales by
Sales in the domestic market increased 18.3% year-over year to
$3.3 billion; international market sales increased 7.9% year-over
year to $3.8 billion. Results included the impact of the recently
concluded Synthes acquisition.
Primary contributors to growth included orthopedic sales from
Synthes products, Biosense Webster's electrophysiology business,
Vistakon's disposable contact lenses and some Specialty Surgery
products. Orthopedics sales increased a whopping 65.5% to $2.3
billion thanks to the Synthes acquisition. The Cardiovascular Care
franchise continued to record a decline in sales reflecting Johnson
& Johnson's exit from the drug-eluting stent market.
Several Medical Devices & Diagnostics markets have been
facing challenges in the form of European austerity measures,
pricing pressure and a slowdown in elective surgeries, which have
all contributed to more tempered growth rates. However, there have
been some signs of improvement in the rate of growth in hospital
admissions and surgeries, including joint replacement.
Pharmaceutical segment sales increased 7.0% year-over-year to
$6.4 billion (operational growth of 11.3% and negative currency
impact of 4.3%). Sales in the domestic market increased 14.6% to
$3.3 billion whereas international sales remained flat at $3.1
The company continued to face a supply problem regarding
Doxil/Caelyx due to third-party manufacturing issues.
Recently launched products like Zytiga, Incivo, Stelara,
Xarelto, Simponi and Invega Sustenna continued to perform well.
Johnson & Johnson also recorded incremental sales due to the
amendment of its distribution agreement with
) for Remicade. Other growth drivers include Prezista as well as
Velcade. Third quarter Zytiga sales were $265 million, up 15.2%
The Consumer segment recorded revenues of $3.6 billion in the
reported quarter, down 4.3% from the third quarter of 2011. Foreign
currency movement negatively impacted sales in the segment by 5.3%.
Sales in the domestic market declined 0.4% year-over-year to $1.2
billion, whereas the international market recorded a 6.1%
year-over-year decline to $2.4 billion.
OTC sales increased 5.7% in the US probably due to the re-launch
of a few key products and the impact of the acquisition of full
ownership rights to certain digestive health products.
2012 Earnings Guidance Up
Following the release of third quarter results, Johnson &
Johnson raised its outlook for 2012. The company now expects
earnings per share of $5.05 - $5.10 in 2012 (old guidance: $5.00 -
$5.07 per share). The Zacks Consensus Estimate currently stands at
$5.06 per share.
Neutral on Johnson & Johnson
We currently have a Neutral recommendation on Johnson &
Johnson. The stock carries a Zacks #2 Rank (Buy rating) in the
short run. Our long-term Neutral recommendation on the stock is
based on the belief that Johnson and Johnson's diversified business
model, lack of cyclicality and strong financial position will help
it in tough situations. Moreover, Johnson & Johnson has been
signing deals, which should help boost its revenues in the long
JOHNSON & JOHNS (JNJ): Free Stock Analysis
MERCK & CO INC (MRK): Free Stock Analysis
To read this article on Zacks.com click here.